Neurotech International (NTI) Share Price & Analysis

11 Followers

NTI Stock Chart & Stats

A$0.02A$0.00(5.26%)

At close: Nov 12 4:00 PM GMT+11

Day’s Range: AUD 0.02 - AUD 0.02
52-Week Range: AUD 0.01 - AUD 0.02
Previous Close: AUD 0.02
Volume: N/A
Average Volume (3M): 5.07M
Market Cap: AUD 30.71M
Enterprise Value: AUD 16.06M
Total Cash (Recent Filing): AUD 2.39M
Total Debt (Recent Filing): AUD 0
Price to Earnings (P/E): ―
Beta: 0.93
Next Earnings: Mar 02, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance Sheet

A debt-free balance sheet reduces leverage pressure and avoids interest obligations while the company develops its pipeline. This provides greater flexibility than a highly indebted structure, although it does not eliminate the need for future funding while operations remain cash consuming.

Focused Proprietary Cannabinoid Pipeline

The company has a defined biotechnology focus centred on proprietary cannabinoid medicines and neurological conditions. Concentration on paediatric neurodevelopmental disorders can support specialised clinical and regulatory expertise, creating a clearer strategic identity for future commercialisation.

Improved Latest-period Free Cash Flow

The material reduction in free-cash-flow outflow indicates some progress in controlling cash consumption during the latest period. If sustained, lower burn could extend funding runway and improve operating resilience, even though the business remains dependent on external capital.

Bears Say

Revenue Fell To Zero

The return to zero annual revenue shows that commercial traction is not yet recurring or dependable. Without a stable sales base, the company has limited internal funding capacity and remains exposed to delays in clinical, regulatory, or commercial progress over the coming periods.

Persistent Operating And Net Losses

Sustained EBIT and net losses indicate that the current cost base is not supported by recurring revenue. Continued losses can consume capital, restrict investment choices, and make future profitability dependent on successful development and commercialisation rather than demonstrated operating performance.

Shrinking Equity And Asset Base

The sharp contraction in equity and total assets reduces the financial cushion available to absorb setbacks or fund development internally. It also reflects the cumulative effect of losses and dilution or retained deficits, increasing reliance on future financing to sustain the business.

Neurotech International News

Neurotech International Reports Change in Director’s Share Interests

Neurotech International ( ($AU:NTI) ) has issued an announcement. Neurotech International Limited disclosed a change in director Andrew Chapman’s direct and indirect interests in the company’s fully paid ordinary shares.

2d agoNTI

Neurotech International Reports Director Departure and Shareholding

Neurotech International ( ($AU:NTI) ) has shared an update. Neurotech International disclosed that Robert Maxwell Johnston ceased serving as a director on 5 November 2026. His final interest notice reported

1w agoNTI

Neurotech Shareholders Back AGM Resolutions

An update from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International said all resolutions at its 5 November annual meeting were decided by poll, with shareholders giving strong

1w agoNTI

Neurotech advances autism drug NTI164 with Phase 3 trial, FDA IND and new funding

Neurotech International ( ($AU:NTI) ) has shared an announcement. Neurotech International has advanced its autism drug candidate NTI164 into pivotal Phase 3 development, dosing the first patient in its national

2w agoNTI

Neurotech Flags High Risks as It Pursues Neurodevelopmental Disorder Therapies

Neurotech International ( ($AU:NTI) ) has issued an update. Neurotech International has outlined its strategic focus on developing treatments for neurodevelopmental disorders, emphasizing the inherent risks and uncertainties in drug

3w agoNTI

Neurotech Director Andrew Chapman Boosts Equity Stake

Neurotech International ( ($AU:NTI) ) has provided an announcement. Neurotech International has disclosed a change in director Andrew Chapman’s relevant interests, detailing adjustments in both direct and indirect holdings of

1M agoNTI

Neurotech International Releases 2026 Annual Report

An announcement from Neurotech International ( ($AU:NTI) ) is now available. Neurotech International has released its 2026 Annual Report, detailing the company’s governance, financial performance, and audited statements for the

1M agoNTI

Neurotech International Sets November AGM, Moves to Digital Meeting Materials

Neurotech International ( ($AU:NTI) ) has provided an update. Neurotech International has called its Annual General Meeting for 5 November 2026 at BDO Australia’s Melbourne offices, with shareholder voting eligibility

1M agoNTI

Neurotech’s NTI164 Autism Trial Enters Phase III: What Investors Should Watch

Neurotech International Ltd. ($AU:NTI) announced an update on their ongoing clinical study. The Phase III study called “A Phase III Double-blind, Randomised, Placebo-controlled Study Investigating the Efficacy and Safety of

1M agoNTI

Neurotech Starts Pivotal Phase 3 Trial of NTI164 for Autism

Neurotech International ( ($AU:NTI) ) has shared an announcement. Neurotech International has begun dosing the first patient in its pivotal Phase 3 Beyond Harmony trial of NTI164 for children with

1M agoNTI

NTI FAQ

What was Neurotech International’s price range in the past 12 months?

Neurotech International lowest share price was AU$0.01 and its highest was AU$0.02 in the past 12 months.

What is Neurotech International’s market cap?

Neurotech International’s market cap is AU$30.71M.

When is Neurotech International’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Neurotech International’s earnings last quarter?

Neurotech International released its earnings results on Sep 02, 2026. The company reported -AU$0.004 earnings per share for the quarter.

Is Neurotech International overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Neurotech International pay dividends?

Neurotech International does not currently pay dividends.

What is Neurotech International’s EPS estimate?

Neurotech International’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Neurotech International have?

Neurotech International has 1,616,070,000 shares outstanding.

What happened to Neurotech International’s price movement after its last earnings report?

Neurotech International reported an EPS of -AU$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Neurotech International?

Currently, no hedge funds are holding shares in AU:NTI

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Neurotech International Stock Smart Score

Neutral

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description